Redburn Atlantic began coverage on shares of Quest Diagnostics (NYSE:DGX – Free Report) in a report issued on Wednesday morning, MarketBeat reports. The firm issued a buy rating and a $195.00 price ...

Shares of Quest Diagnostics Inc. DGX slid 3.78% to $164.18 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 5.97% to 5,074.08 ...

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine ...

In the longer term, DGX stock is up 10.5% on a YTD basis, outpacing SPX’s 2.9% dip. Moreover, shares of Quest Diagnostics have surged 29.3% over the past 52 weeks, compared to the 9.8% return ...

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the testing & diagnostics services stocks, including ...

Analysts have set 12-month price targets for Quest Diagnostics, revealing an average target of $179.44, a high estimate of ...

Shares of Quest Diagnostics Inc. DGX shed 1.39% to $173.12 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 2.70% to 5,614. ...

Quest Diagnostics Inc. DGX benefits from its robust ... A strong focus on operational excellence is highly encouraging for the stock. Meanwhile, the adverse impacts of the broader industry ...

The stock, currently trading near its 52 ... The securities firm's analysis indicates that Quest Diagnostics is expected to continue its positive trajectory, supported by several key factors.

Thrivent Financial for Lutherans decreased its stake in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 7.1% ...

stock has rallied 25.2% compared with the industry’s 2.9% growth and the S&P 500 composite’s 10.6% rise. The renowned provider of diagnostic information services has a market capitalization of $18.38 ...